Beta cellulin Polyclonal Antibody
Applications
Predicted Reactivity
| Overview | |
| Catalog # | bs-12864R |
| Product Name | Beta cellulin Polyclonal Antibody |
| Applications |
WB
ELISA
IHC-P
IHC-F
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Predicted Reactivity | Human |
| Specifications | |
| Conjugation | Unconjugated |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human Betacellulin |
| Immunogen Range | 1-100/178 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles. |
| Target | |
| Gene ID | 685 |
| Subcellular location | Secreted, Cell membrane, Extracellular matrix |
| Synonyms | Beta cellulin; Beta cellulin precursor; BTC; BTC_HUMAN; OTTHUMP00000160600; OTTHUMP00000219057; Probetacellulin. |
| Background | Betacellulin (BTC), a member of the epidermal growth factor (EGF) family, was originally identified as a growth-promoting factor in the conditioned medium of a mouse pancreatic-cell carcinoma (insulinoma) cell line and has since been identified in humans. BTC is synthesized as a large transmembrane precursor molecule that can be cleaved proteolytically to release the soluble form of BTC or function as membrane-anchored growth factors in juxtacrine signaling. BTC, in addition to stimulating homodimers of ErbB-1 and ErbB-4, is capable of binding and activating all possible combinations of heterodimeric ErbB receptors including the oncogenic ErbB-2/ErbB-3 complex. BTC is also expressed in some human malignancies and may have an important role in tumor growth progression. |
| Application Dilution | |
| WB | 1:300-5000 |
| ELISA | 1:500-1000 |
| IHC-P | 1:200-400 |
| IHC-F | 1:100-500 |
| IF(IHC-P) | 1:50-200 |
| IF(IHC-F) | 1:50-200 |
| IF(ICC) | 1:50-200 |